Generally, in patients with GH-secreting pituitary microadenomas or small tumor remnants, medical therapy can be safely withdrawn shortly after pregnancy confirmation [112, 117], carefully monitoring clinical symptoms of potential tumor enlargement (visual field); whereas in those with macroadenomas at high risk of tumor growth, medical therapy can be maintained throughout the pregnancy [112, 117]. The gene discussed is GH1; the disease is neoplasm.